Compare iShares MSCI Germany (DAX) (EWG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Novo Nordisk A/S — how do they compare? iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 116.4× iShares MSCI Germany (DAX)'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Novo Nordisk A/S for 116 Days on average.
| EWG | NVO | |
|---|---|---|
Market Cap | $1.42B | $165.31B |
Volume | 1,110,573 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $63.98 |
52-Week Low | $38.08 | $35.29 |
Typical Hold Time | 54 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.67, down 0.59% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $41 with support at $40. Recent European market news highlights ECB rate hikes and energy price concerns affecting regional equities, though some analysts note resilience in European stocks despite macroeconomic pressures.
The bearish technical indicators and European economic uncertainty create near-term headwinds. Investment opportunity exists if the stock holds above $40 support, but risks include further ECB tightening and energy-driven inflation. Upside potential requires breaking above $41 resistance with improved market sentiment toward European equities.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
